SCHEMBL5497767

SCHEMBL5497767

CN(C)CCCN(C)c1ccc(C(F)(F)F)cc1NC(=O)c1cc(-c2ccc3nc(N)ncc3c2)ccc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 13/20 0.59
KDR P35968 10/20 0.59
TEK Q02763 7/20 0.59
MAPK14 Q16539 6/20 0.44
JAK3 P52333 5/20 0.44
SRC P12931 2/20 0.43
AURKA O14965 1/20 0.43
ABL1 P00519 1/20 0.43
EGFR P00533 1/20 0.43
NTRK1 P04629 1/20 0.43
INSR P06213 1/20 0.43
FES P07332 1/20 0.43
CSF1R P07333 1/20 0.43
LYN P07948 1/20 0.43
RET P07949 1/20 0.43
IGF1R P08069 1/20 0.43
MET P08581 1/20 0.43
PDGFRB P09619 1/20 0.43
FGR P09769 1/20 0.43
AKT1 P31749 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5493788 0.92 LCK (0.60) LCKKDRTEKMAPK14JAK3
SCHEMBL5492672 0.92 LCK (0.70) LCKKDRTEKMAPK14JAK3
SCHEMBL5501414 0.91 LCK (0.59) LCKKDRTEKMAPK14JAK3
SCHEMBL5501160 0.89 LCK (0.59) LCKKDRTEKMAPK14JAK3
SCHEMBL5501955 0.89 LCK (0.56) LCKKDRTEKMAPK14JAK3
SCHEMBL5496542 0.89 LCK (0.57) LCKKDRTEKMAPK14JAK3
SCHEMBL5498672 0.88 LCK (0.55) LCKKDRTEKMAPK14JAK3
SCHEMBL5502214 0.87 LCK (0.64) LCKKDRTEKMAPK14JAK3
SCHEMBL5497764 0.87 LCK (0.49) LCKKDRTEKMAPK14JAK3
SCHEMBL5502527 0.87 LCK (0.56) LCKKDRTEKMAPK14JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP claimed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US claimed
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP disclosed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 LCK 106/4885KDR 1044/4885TEK 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.